|1.||Yeh, Li-Tain: 2 articles (09/2006 - 03/2005)|
|2.||Hynicka, Lauren M: 1 article (07/2010)|
|3.||Patel, Punam H: 1 article (07/2010)|
|4.||Yunker, Nancy: 1 article (07/2010)|
|5.||van Poelje, Paul D: 1 article (02/2008)|
|6.||Craigo, William: 1 article (02/2008)|
|7.||Ugarkar, Bheemarao G: 1 article (02/2008)|
|8.||Erion, Mark D: 1 article (02/2008)|
|9.||Colby, Timothy J: 1 article (02/2008)|
|10.||Gómez-Galeno, Jorge E: 1 article (02/2008)|
|1.||Chronic Hepatitis B
01/01/2005 - "In addition, several novel anti-HBV agents recently evaluated in phase II clinical trials, such as tenofovir, clevudine, telbivudine, pradefovir, and valtorcitabine, appear to be promising agents for the treatment of chronic hepatitis B. "
07/01/2010 - "A search from 1950 to April 2010 was conducted using the databases PubMed and MEDLINE with the search terms chronic hepatitis B, lamivudine, entecavir, adefovir, telbivudine, tenofovir, emtricitabine, clevudine, and pradefovir. "
|2.||Body Weight (Weight, Body)
03/01/2005 - "Single-dose pharmacokinetics and metabolism of [(14)C]remofovir was studied in rats and monkeys following intravenous (i.v.) and oral administration (30 mg/kg of body weight). "
09/01/2006 - "Daily oral dosing (300 mg/kg of body weight) to rats for 8 days showed that pradefovir was not an inducer of P450 enzymes in rats. "
08/01/2007 - "Pradefovir, a liver-targeted prodrug of adefovir against HBV infection."
08/01/2007 - "Metabasis Therapeutics Inc (previously Ribapharm Inc) is developing pradefovir, an oral liver-targeting prodrug of adefovir developed using its HepDirect technology, for the potential treatment of HBV infection. "